Compile Data Set for Download or QSAR
maximum 50k data
Found 502 Enz. Inhib. hit(s) with all data for entry = 62
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111084(US9682940, 17 | US9682940, 26)
Affinity DataEC50:  6nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111084(US9682940, 17 | US9682940, 26)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111098(US9682940, 19)
Affinity DataEC50:  84nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111098(US9682940, 19)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111105(US9682940, 20)
Affinity DataEC50:  165nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111105(US9682940, 20)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111124(US9682940, 21)
Affinity DataEC50:  170nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111124(US9682940, 21)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111128(US9682940, 22)
Affinity DataEC50:  249nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111128(US9682940, 22)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111130(US9682940, 23)
Affinity DataEC50:  2.15E+3nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111130(US9682940, 23)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111132(US9682940, 24)
Affinity DataEC50:  151nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111132(US9682940, 24)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111134(US9682940, 25)
Affinity DataEC50:  1.23E+3nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111134(US9682940, 25)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111084(US9682940, 17 | US9682940, 26)
Affinity DataEC50:  5nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111084(US9682940, 17 | US9682940, 26)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111136(US9682940, 27)
Affinity DataEC50:  410nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111136(US9682940, 27)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111138(US9682940, 28)
Affinity DataEC50:  134nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111138(US9682940, 28)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111139(US9682940, 29)
Affinity DataEC50:  1.49E+3nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111139(US9682940, 29)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111140(US9682940, 30)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111140(US9682940, 30)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111141(US9682940, 31)
Affinity DataEC50:  128nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111141(US9682940, 31)
Affinity DataEC50:  2.34E+3nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111142(US9682940, 32)
Affinity DataEC50:  71nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111142(US9682940, 32)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111143(US9682940, 33)
Affinity DataEC50:  49nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111143(US9682940, 33)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111144(US9682940, 34)
Affinity DataEC50:  6.03E+3nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111144(US9682940, 34)
Affinity DataEC50:  7.50E+3nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111145(US9682940, 173 | US9682940, 35)
Affinity DataEC50:  5nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111145(US9682940, 173 | US9682940, 35)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111146(US9682940, 37)
Affinity DataEC50:  8nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111146(US9682940, 37)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111147(US9682940, 38)
Affinity DataEC50:  12nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111147(US9682940, 38)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111148(US9682940, 39)
Affinity DataEC50:  144nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111148(US9682940, 39)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111149(US9682940, 40)
Affinity DataEC50:  297nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111149(US9682940, 40)
Affinity DataEC50:  1.02E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111150(US9682940, 41)
Affinity DataEC50:  1.65E+3nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM111150(US9682940, 41)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM113302(US9682940, 42)
Affinity DataEC50:  6nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM113302(US9682940, 42)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM113303(US9682940, 43)
Affinity DataEC50:  169nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM113303(US9682940, 43)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 502 total ) | Next | Last >>
Jump to: